Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (11-20 of 324) with videos related to

Pageof 33
Sort By:
Lancet (London, England)|January 10, 2018
Combination ART: are two drugs as good as three?Mark A Boyd, David A Cooper
AIDS (London, England)|September 25, 2007
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical researchMark A Boyd, David A Cooper
The Lancet. HIV|April 3, 2016
Tenofovir alafenamide: safer, but questions remainMark A Boyd, David A Cooper
AIDS (London, England)|November 10, 2017
Reducing medical comorbidities associated with long-term HIV infection: beyond optimizing antiretroviral therapy regimensNila J Dharan, David A Cooper
The Lancet. Infectious Diseases|July 24, 2015
The LATTE study: a provocative brewMark Alastair Boyd, David A Cooper
JAMA|July 20, 2014
Integrating HIV prevention into practiceBradley M Mathers, David A Cooper
Lancet (London, England)|August 8, 2006
HAART's first decade: success brings further challengesGregory J Dore, David A Cooper
Marine Pollution Bulletin|January 29, 2010
Effects of mechanical and chemical processes on the degradation of plastic beach debris on the island of Kauai, HawaiiDavid A Cooper, Patricia L Corcoran
Lancet (London, England)|July 29, 2017
Long-acting injectable ART: next revolution in HIV?Mark A Boyd, David A Cooper
Lancet (London, England)|July 26, 2012
Optimisation of HIV care and service delivery: doing more with lessMark A Boyd, David A Cooper
Pageof 33

Showing results (11-20 of 324) with videos related to

Sort By:
Pageof 33
Lancet (London, England)|January 10, 2018
Combination ART: are two drugs as good as three?Mark A Boyd, David A Cooper
AIDS (London, England)|September 25, 2007
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical researchMark A Boyd, David A Cooper
The Lancet. HIV|April 3, 2016
Tenofovir alafenamide: safer, but questions remainMark A Boyd, David A Cooper
AIDS (London, England)|November 10, 2017
Reducing medical comorbidities associated with long-term HIV infection: beyond optimizing antiretroviral therapy regimensNila J Dharan, David A Cooper
The Lancet. Infectious Diseases|July 24, 2015
The LATTE study: a provocative brewMark Alastair Boyd, David A Cooper
JAMA|July 20, 2014
Integrating HIV prevention into practiceBradley M Mathers, David A Cooper
Lancet (London, England)|August 8, 2006
HAART's first decade: success brings further challengesGregory J Dore, David A Cooper
Marine Pollution Bulletin|January 29, 2010
Effects of mechanical and chemical processes on the degradation of plastic beach debris on the island of Kauai, HawaiiDavid A Cooper, Patricia L Corcoran
Lancet (London, England)|July 29, 2017
Long-acting injectable ART: next revolution in HIV?Mark A Boyd, David A Cooper
Lancet (London, England)|July 26, 2012
Optimisation of HIV care and service delivery: doing more with lessMark A Boyd, David A Cooper
Pageof 33